ClinicalTrials.gg
CompletedNCT05004675LIBerate-VIUpdated Oct 23, 2024

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

A Phase 3 interventional study of lerodalcibep and Inclisiran in Hypercholesterolemia and Atherosclerotic Ischemic Disease, sponsored by LIB Therapeutics LLC. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by LIB Therapeutics LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Hypercholesterolemia with a site in France — 4 open to participants now, 9 under way, 5 of them phase 3. Hypercholesterolemia · France.

Enrollment
34th of 60
166 · median 301
Started
2022
with 3 others
Phase 3
33 of 64
1 open now
Registered
49th of 64
by date

Among the 64 studies in Hypercholesterolemia with a site in France, this one is the 34th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2022, is one of 33 in phase 3, and was the 49th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

4 of the 64 studies in Hypercholesterolemia with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Hypercholesterolemia with a site in France, or all of them as a file.
02

Study summary

Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug therapy

Read the detailed description

Randomized, Open Label (lipids blinded), Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) at Day 270 of subcutaneous (SC) monthly (QM [≤31 days]) lerodalcibep (LIB003) 300 mg administered to SC inclisiran (Leqvio®) 284 mg at Days 1 and 90 in patients with very-high risk or high-risk CVD or at high risk for CVD with LDL-C ≥85 mg/dL on a stable diet and oral LDL-C-lowering drug therapy

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerotic Ischemic Disease

Keywords

  • lerodalcibep
  • PCSK9 inhibitor
  • inclisiran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study-specific procedure;
  • Weight of ≥40 kg (88 lb) and (BMI) ≥16 and ≤42 kg/m2;
  • Very- high or high risk for CVD as defined in 2019 ESC/EAS Guidelines
  • High-intensity statin (daily atorvastatin 40/80 or rosuvastatin 20/40) without other acceptable oral lipid lowering treatment plus diet; stable >4 weeks with LDL-C ≥85 mg/dL and triglycerides ≤400 mg/dL
  • Women of (WOCBP) must continue using a highly effective form of if sexually active
  • Males whose partners are of CBP and not using a highly effective form of birth control will either be surgically sterile or agree to use the following forms of contraception, male or female condom with spermicide

Exclusion criteria

Exclusion Criteria:

  • Prior or active clinical condition or acute and/or unstable systemic disease, including cancer, compromising patient inclusion or preclude completion of the study, at the discretion of the Investigator
  • Homozygous FH
  • non-high intensity statins, mipomersen, lomitapide, gemfibrozil, and bempedoic acid
  • PCSK9 mAb within 4 weeks of screening or siRNA within 1 year
  • Severe renal dysfunction, defined \<30 ml/min
  • Recent, within 3 months of screening, atherosclerotic event or intervention
  • planned cardiac procedure
  • class III or IV heart failure
  • active liver disease
  • uncontrolled diabetes defined as fasting glucose >200 mg/dL and > 9%
  • uncontrolled BP ≥180 mmHg systolic or ≥110 mmHg diastolic;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    lerodalcibep

    300 mg SC dosed monthly

    Biological: lerodalcibep

  • Active comparator
    inclisiran

    284 mg SC dosed Day 1 and Day 90

    Drug: Inclisiran

Interventions

06

What researchers measure

Primary outcomes

  1. LDL-C change

    Percent LDL-C change from baseline

    Time frame: Day 270

Secondary outcomes

  1. Adverse Events

    frequency and severity of injection site reactions (ISRs)

    Time frame: 270 days

  2. Serum free PCSK9 levels

    Percent change in free PCSK9 from baseline

    Time frame: Day 270

  3. Apolipoproteins

    Percent change in Apo B and Lp(a) from baseline

    Time frame: Day 270

  4. Treatment goal achievement

    Percent of patients reaching ESC/EAS treatment goals

    Time frame: Day 270

07

Study locations

7 sites
  • CHU de Nantes - Hôpital Nord Laennec
    Nantes, Cedex 01 44093, France
  • Hopitaux de Marseille
    Marseille, Cedex 05 13385, France
  • Universitätsklinikum Heidelberg - Medizinische Klinik
    Heidelberg, 69120, Germany
  • The Lipid Clinic (Oslo University Hospital)
    Oslo, Nydalen 424, Norway
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Oak Tree Surgery and Pensilva Health Centre
    Liskeard, Cornwall PL14 3XA, United Kingdom
  • Ashton Medical Group
    Ashton-Under-Lyne, Lancashire OL6 6EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2024, 23 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 13, 2021
StartActual
Jun 20, 2022
Primary completionActual
May 30, 2024
CompletionActual
Oct 15, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05004675
Lead sponsor
LIB Therapeutics LLC
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Jun 20, 2022
Primary completion
May 30, 2024
Completion
Oct 15, 2024
Last update
Oct 23, 2024

Study contacts

Evan A Stein, MD PhD
study director · LIB Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion